EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis

Koki Sasamoto iD, Ken-Ichi Nagakura iD, Tomoyuki Asaumi iD, Naoko Fusayasu iD, Katsuyo Ohashi-Doi iD, Noriyuki Yanagida iD, Sakura Sato iD, Motohiro Ebisawa iD

Pediatric Allergy and Immunology · 2024

DOI: 10.1111/pai.14203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, 2024. Verfasst von Koki Sasamoto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Minami-ku Sagamihara, Japan. Hauptthemen laut MEDLINE: Sublingual Immunotherapy, Pyroglyphidae, Antigens, Dermatophagoides, Rhinitis, Allergic, Perennial. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sublingual immunotherapy (SLIT) for perennial allergic rhinitis (AR) has not been extensively studied in preschoolers. We investigated the efficacy and safety of house dust mite (HDM) SLIT‐tablet for children aged 1–4 years.

Methods

Children aged 1–4 years with AR were divided into SLIT ( n = 22) and control ( n = 12) groups based on their guardians' preferences. The SLIT group received a daily dose of 10,000 JAU of HDM SLIT‐tablet for 12 months, whereas the control group received symptomatic treatment only.

Results

The baseline median age was 41 and 34 months in the SLIT and control groups, respectively, and the median AR symptom score was 4 for both groups. Compared with baseline, the AR symptom score had decreased significantly in the SLIT group after 12 months (score: 3, p = .002), whereas it tended to increase in the control group (score: 6, p = .08). Adverse reactions to SLIT were mild and occurred in eight patients (36%). In the SLIT group, Dermatophagoides ( D. ) farinae ‐specific IgE (sIgE) levels increased during the first 6 months and decreased to baseline levels at 12 months. In the control group, D. farinae ‐sIgE levels had increased significantly at 12 months compared to baseline ( p = .01). D. farinae‐ specific IgG 4 and HDM IgE‐blocking factor levels were significantly increased at 12 months compared to baseline in the SLIT group only ( p < .001). A lower wheezing frequency was seen in the SLIT group (0.3%) compared to the control group (0.7%).

Conclusion

This pilot study demonstrated the efficacy, safety, and immunomodulatory effects of HDM SLIT‐tablet in preschoolers with AR. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sublingual ImmunotherapyPyroglyphidaeAntigens, DermatophagoidesRhinitis, Allergic, PerennialHumansChild, PreschoolAnimalsMaleFemaleInfantTreatment OutcomeImmunoglobulin ETablets

Stichwörter der Autor:innen

IgE‐blocking factorallergen immunotherapyhouse dust mitepreschool childrensublingual immunotherapy

Substanzen

Antigens, DermatophagoidesImmunoglobulin ETablets

Autor:innen und Institutionen

  • Department of Allergy, Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Minami-ku Sagamihara, Japan.
  • Department of Pediatrics, Toho University Ohashi Medical Center, Meguro-ku, Japan.
  • Torii Pharmaceutical Co., Ltd., Chuo-ku, Japan.

ORCID-Profile: Koki Sasamoto, Ken-Ichi Nagakura, Tomoyuki Asaumi, Naoko Fusayasu, Katsuyo Ohashi-Doi, Noriyuki Yanagida, Sakura Sato, Motohiro Ebisawa

Zitieren

APA

Sasamoto, K., Nagakura, K. I., Asaumi, T., Fusayasu, N., Ohashi-Doi, K., Yanagida, N., Sato, S., & Ebisawa, M. (2024). Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.14203

Vancouver

Sasamoto K, Nagakura KI, Asaumi T, Fusayasu N, Ohashi-Doi K, Yanagida N, et al. Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis. Pediatric Allergy and Immunology. 2024. doi:10.1111/pai.14203

BibTeX
@article{Sasamoto2024,
  author = {Sasamoto, Koki and Nagakura, Ken-Ichi and Asaumi, Tomoyuki and Fusayasu, Naoko and Ohashi-Doi, Katsuyo and Yanagida, Noriyuki and Sato, Sakura and Ebisawa, Motohiro},
  title = {Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis},
  journal = {Pediatric Allergy and Immunology},
  year = {2024},
  doi = {10.1111/pai.14203}
}
Kostenlos starten →